TNFRSF8
ENSG00000120949
Target class
Secreted protein
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Other names
- KI-1
- Target name
- TNFRSF8
- Gene name
- TNF receptor superfamily member 8
- Gene symbol
- TNFRSF8
- Protein name
- Tumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen) (Lymphocyte activation antigen CD30) (CD antigen CD30)
- CD30
- D1S166E
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor receptor superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 18
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 90.13
- Tissue specificity (Gini)
- 0.831
- Tissue specificity (tau)
- 0.988
- KEGG gene identifiers
- hsa:943
- Reactome pathways
- R-HSA-5669034
- Protein interaction confidence
- 0.821718
- Protein interaction partners
- 39
- End position
- 12144207
- Start position
- 12063303
- Chromosome
- 1
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm .
- Plasma membrane
- PubMed 8391931
- PubMed 8999898
- PubMed 8839832
- Tissue specificity (tau)
- 0.988375
- Expression inequality (Gini)
- 0.831353
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 90.13
- Adipose - Subcutaneous
- 6.59
- Adipose - Visceral (Omentum)
- 5.53
- Whole Blood
- 4.84
- Breast - Mammary Tissue
- 4.05
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes90.13
- Adipose - Subcutaneous6.59
- Adipose - Visceral (Omentum)5.53
- Whole Blood4.84
- Breast - Mammary Tissue4.05
- Testis3.94
- Brain - Nucleus accumbens (basal ganglia)2.65
- Nerve - Tibial2.08
- Brain - Caudate (basal ganglia)1.98
- Spleen1.93
- Brain - Putamen (basal ganglia)1.67
- Fallopian Tube1.27
- Uterus1.25
- Heart - Atrial Appendage1.23
- Skin - Sun Exposed (Lower leg)1.17
- Lung1.12
- Artery - Coronary1.07
- Esophagus - Muscularis1.01
- Esophagus - Gastroesophageal Junction0.99
- Stomach0.98
- Small Intestine - Terminal Ileum0.83
- Bladder0.76
- Skin - Not Sun Exposed (Suprapubic)0.76
- Artery - Tibial0.71
- Colon - Sigmoid0.63
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0008285
- GO:0032759
- GO:0032760
- GO:0043065
- GO:0071260
- GO:0005737
- GO:0005886
- GO:0070062
- GO:0002020
- GO:0004888
- GO:0005515
Related records
Trials (199)
- A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
- A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
- A Comparative Study on Local Allergic Responses of Bee Venom and Essential Bee Venom Pharmacopuncture
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
- A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
- A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
- A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
- A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
- A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
- A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
- A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
- A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
- A Safety Study of Brentuximab Vedotin in Participants With HIV
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
- A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Drugs (4)
- Brentuximab vedotin Tumor necrosis factor receptor superfamily member 8 binding agent
- HEFI-1 Tumor necrosis factor receptor superfamily member 8 binding agent
- Iratumumab Tumor necrosis factor receptor superfamily member 8 other
- SGN-30 Tumor necrosis factor receptor superfamily member 8 agonist